Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.44 |
| ▸ | THRA | P10827 | 8/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933178 | 0.93 | THRB (0.48) | THRBTHRATRPA1CYP1A2MME | |
| SCHEMBL4923914 | 0.90 | TRPA1 (0.42) | TRPA1CYP1A2MMEACECPA1 | |
| SCHEMBL4928651 | 0.89 | THRB (0.46) | THRBTHRAMMEACECPA1 | |
| SCHEMBL5119332 | 0.87 | THRB (0.43) | THRBTHRAMMEACECPA1 | |
| SCHEMBL5112643 | 0.87 | THRA (0.44) | THRBTHRAMMEACECPA1 | |
| SCHEMBL4930958 | 0.87 | THRA (0.44) | THRBTHRATRPA1MMEACE | |
| SCHEMBL4931744 | 0.87 | THRB (0.42) | THRBTHRATRPA1 | |
| SCHEMBL5106574 | 0.86 | THRB (0.42) | THRBTHRAMMEACECPA1 | |
| SCHEMBL4930935 | 0.86 | MME (0.42) | THRBTHRAMMEACECPA1 | |
| SCHEMBL4932092 | 0.85 | THRB (0.51) | THRBTHRATRPA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885TRPA1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.